The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …

Human endogenous retroviruses (HERVs) are abundant sequences that persist within the
human genome as remnants of ancient retroviral infections. These sequences became fixed …

Tertiary lymphoid structures (TLS) are transient ectopic lymphoid aggregates where
adaptive antitumour cellular and humoral responses can be elaborated. Initially described in …

Tertiary lymphoid structures (TLSs) are associated with enhanced immunity in tumors.
However, their formation and functions in colorectal cancer liver metastasis (CRLM) remain …

Association with hypomethylating agents is a promising strategy to improve the efficacy of
immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation …

Cancer has long been viewed as a genetic disease of cumulative mutations. This notion is
fuelled by studies showing that ageing tissues are often riddled with clones of complex …

Over the past decade, RAS oncogenic proteins have transitioned from being deemed
undruggable to having two clinically approved drugs, with several more in advanced stages …

Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous
mutations present within the cancer genome, varies across and within cancer types. A first …

Abstract Long interspersed element 1 (LINE-1) is the only protein-coding transposon that is
active in humans. LINE-1 propagates in the genome using RNA intermediates via …

Immunotherapy has emerged as a crucial strategy to combat cancer by “reprogramming” a
patient's own immune system. Although immunotherapy is typically reserved for patients with …